
Glenmark’s Innovation Spin-Off IGI Gets FDA Fast Track for Blood Cancer Drug
New York: Ichnos Glenmark Innovation (IGI), a clinical-stage biotechnology company jointly incubated by Glenmark Pharmaceuticals and Ichnos Sciences, has received Fast Track designation from the US Food and Drug Administration (FDA) for its blood cancer …